Generation of BiKEs and TriKEs to improve NK cell-mediated targeting of tumor cells

Methods in Molecular Biology

Volumn 1441, Issue , 2016, Pages 333-346

  Felices, Martin ^a   Lenvik, Todd R ^a   Davis, Zachary B ^a   Miller, Jeffrey S ^a   Vallera, Daniel A ^a  

^a NONE

Author keywords

ADCC; Bi specific; BiKE; Natural killer; NK; Redirected lysis; Targeted immunotherapy; Tri specific; TriKE

Indexed keywords

BI SPECIFIC KILLER ENGAGER; BISPECIFIC ANTIBODY; MONOCLONAL ANTIBODY; TRI SPECIFIC KILLER ENGAGER; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY SPECIFICITY; ANTIGEN BINDING; CANCER IMMUNOTHERAPY; CROSS LINKING; DRUG ISOLATION; EXPRESSION VECTOR; FLOW CYTOMETRY; GENE EXPRESSION SYSTEM; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR CLONING; NATURAL KILLER CELL; NONHUMAN; TARGET CELL; TUMOR CELL; ADOPTIVE IMMUNOTHERAPY; CELL CULTURE; IMMUNOLOGY; METABOLISM; NEOPLASM; TRANSPLANTATION; TUMOR CELL LINE;

ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; CELLS, CULTURED; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; NEOPLASMS;

EID: 84979233610     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-3684-7_28     Document Type: Chapter

References (96)

1. Masters GA, Krilov L, Bailey HH et al (2015) Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol 33:786–809
2. Caruana I, Diaconu I, Dotti G (2014) From monoclonal antibodies to chimeric antigen receptors for the treatment of human malignancies. Semin Oncol 41:661–666
3. Hermanson DL, Kaufman DS (2015) Utilizing chimeric antigen receptors to direct natural killer cell activity. Front Immunol 6:195
4. Glienke W, Esser R, Priesner C et al (2015) Advantages and applications of CAR-expressing natural killer cells. Front Pharmacol 6:21
5. Vivier E, Raulet DH, Moretta A et al (2011) Innate or adaptive immunity? The example of natural killer cells. Science 331:44–49
6. Velardi A (2012) Natural killer cell alloreactivity 10 years later. Curr Opin Hematol 19:421–426
7. Anegon I, Cuturi MC, Trinchieri G et al (1988) Interaction of Fc receptor (CD16) ligands induces transcription of interleukin 2 receptor (CD25) and lymphokine genes and expression of their products in human natural killer cells. J Exp Med 167:452–472
8. Ravetch JV, Bolland S (2001) IgG Fc receptors. Annu Rev Immunol 19:275–290
9. Selvaraj P, Carpen O, Hibbs ML et al (1989) Natural killer cell and granulocyte Fc gamma receptor III (CD16) differ in membrane anchor and signal transduction. J Immunol 143:3283–3288
10. Perussia B, Ravetch JV (1991) Fc gamma RIII (CD16) on human macrophages is a functional product of the Fc gamma RIII-2 gene. Eur J Immunol 21:425–429
11. Klaassen RJ, Ouwehand WH, Huizinga TW et al (1990) The Fc-receptor III of cultured human monocytes. Structural similarity with FcRIII of natural killer cells and role in the extracellular lysis of sensitized erythrocytes. J Immunol 144:599–606
12. Nishikiori N, Koyama M, Kikuchi T et al (1993) Membrane-spanning Fc gamma receptor III isoform expressed on human placental trophoblasts. Am J Reprod Immunol 29:17–25
13. Ravetch JV, Perussia B (1989) Alternative membrane forms of Fc gamma RIII(CD16) on human natural killer cells and neutrophils. Cell type-specific expression of two genes that differ in single nucleotide substitutions. J Exp Med 170:481–497
14. Lanier LL, Ruitenberg JJ, Phillips JH (1988) Functional and biochemical analysis of CD16 antigen on natural killer cells and granulocytes. J Immunol 141:3478–3485
15. Wirthmueller U, Kurosaki T, Murakami MS et al (1992) Signal transduction by Fc gamma RIII (CD16) is mediated through the gamma chain. J Exp Med 175:1381–1390
16. Cooper MA, Fehniger TA, Caligiuri MA (2001) The biology of human natural killercell subsets. Trends Immunol 22:633–640
17. Beziat V, Duffy D, Quoc SN et al (2011) CD56brightCD16+ NK cells: a functional intermediate stage of NK cell differentiation. J Immunol 186:6753–6761
18. Vivier E, Nunes JA, Vely F (2004) Natural killer cell signaling pathways. Science 306:1517–1519
19. Vivier E, Morin P, O’Brien C et al (1991) Tyrosine phosphorylation of the Fc gamma RIII(CD16): zeta complex in human natural killer cells. Induction by antibody-dependent cytotoxicity but not by natural killing. J Immunol 146:206–210
20. Nimmerjahn F, Ravetch JV (2008) Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 8:34–47
21. Bryceson YT, Ljunggren HG, Long EO (2009) Minimal requirement for induction of natural cytotoxicity and intersection of activation signals by inhibitory receptors. Blood 114:2657–2666
22. Shore SL, Nahmias AJ, Starr SE et al (1974) Detection of cell-dependent cytotoxic antibody to cells infected with herpes simplex virus. Nature 251:350–352
23. Laszlo A, Petri I, Ilyes M (1986) Antibody dependent cellular cytotoxicity (ADCC)- reaction and an in vitro steroid sensitivity test of peripheral lymphocytes in children with malignant haematological and autoimmune diseases. Acta Paediatr Hung 27:23–29
24. Natsume A, Niwa R, Satoh M (2009) Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC. Drug Des Devel Ther 3:7–16
25. Albertini MR, Hank JA, Sondel PM (2005) Native and genetically engineered antidisialoganglioside monoclonal antibody treatment of melanoma. Cancer Chemother Biol Response Modif 22:789–797
26. Garcia-Foncillas J, Diaz-Rubio E (2010) Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome. Clin Trans Oncol 12:533–542
27. Garnock-Jones KP, Keating GM, Scott LJ (2010) Trastuzumab: A review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. Drugs 70:215–239
28. Navid F, Santana VM, Barfield RC (2010) Anti-GD2 antibody therapy for GD2- expressing tumors. Curr Cancer Drug Targets 10:200–209
29. Winter MC, Hancock BW (2009) Ten years of rituximab in NHL. Expert Opin Drug Saf 8:223–235
30. Congy-Jolivet N, Bolzec A, Ternant D et al (2008) Fc gamma RIIIa expression is not increased on natural killer cells expressing the Fc gamma RIIIa-158V allotype. Cancer Res 68:976–980
31. Moore GL, Bautista C, Pong E et al (2011) A novel bispecific antibody format enables simultaneous bivalent and monovalent coengagement of distinct target antigens. MAbs 3:546–557
32. Preithner S, Elm S, Lippold S et al (2006) High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G. Mol Immunol 43:1183–1193
33. Baselga J, Albanell J (2001) Mechanism of action of anti-HER2 monoclonal antibodies. Ann Oncol 12(Suppl 1):S35–S41
34. Berinstein NL, Grillo-Lopez AJ, White CA et al (1998) Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent lowgrade or follicular non-Hodgkin’s lymphoma. Ann Oncol 9:995–1001
35. Holliger P, Hudson PJ (2005) Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23:1126–1136
36. Chames P, Van Regenmortel M, Weiss E et al (2009) Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol 157:220–233
37. Scott AM, Wolchok JD, Old LJ (2012) Antibody therapy of cancer. Nat Rev Cancer 12:278–287
38. Ferrini S, Cambiaggi A, Cantoni C et al (1992) Targeting of T or NK lymphocytes against tumor cells by bispecific monoclonal antibodies: role of different triggering molecules. Int J Cancer 7:15–18
39. Glorius P, Baerenwaldt A, Kellner C et al (2013) The novel tribody [(CD20)(2)xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells. Leukemia 27:190–201
40. Kipriyanov SM, Cochlovius B, Schafer HJ et al (2002) Synergistic antitumor effect of bispecific CD19 x CD3 and CD19 x CD16 diabodies in a preclinical model of non-Hodgkin’s lymphoma. J Immunol 169:137–144
41. Kellner C, Bruenke J, Stieglmaier J et al (2008) A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells. J Immunother 31:871–884
42. Kellner C, Bruenke J, Horner H et al (2011) Heterodimeric bispecific antibody-derivatives against CD19 and CD16 induce effective antibody- dependent cellular cytotoxicity against B-lymphoid tumor cells. Cancer Lett 303:128–139
43. Portner LM, Schonberg K, Hejazi M et al (2012) T and NK cells of B cell NHL patients exert cytotoxicity against lymphoma cells following binding of bispecific tetravalent antibody CD19 x CD3 or CD19 x CD 16. Cancer Immunol Immunother 61:1869–1875
44. Bruenke J, Barbin K, Kunert S et al (2005) Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16). Br J Haematol 130:218–228
45. Johnson S, Burke S, Huang L et al (2010) Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion. J Mol Biol 399:436–449
46. Schlenzka J, Moehler TM, Kipriyanov SM et al (2004) Combined effect of recombinant CD19 x CD16 diabody and thalidomide in a preclinical model of human B cell lymphoma. Anticancer Drugs 15:915–919
47. Schubert I, Kellner C, Stein C et al (2012) A recombinant triplebody with specificity for CD19 and HLA-DR mediates preferential binding to antigen double-positive cells by dual-targeting. MAbs 4:45–56
48. Schubert I, Kellner C, Stein C et al (2011) A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targeting. MAbs 3:21–30
49. Silla LM, Chen J, Zhong RK et al (1995) Potentiation of lysis of leukaemia cells by a bispecific antibody to CD33 and CD16 (Fc gamma RIII) expressed by human natural killer (NK) cells. Br J Haematol 89:712–718
50. Singer H, Kellner C, Lanig H et al (2010) Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD 16. J Immunother 33:599–608
51. Kugler M, Stein C, Kellner C et al (2010) A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting. Br J Haematol 150:574–586
52. Bruenke J, Fischer B, Barbin K et al (2004) A recombinant bispecific single-chain Fv antibody against HLA class II and FcgammaRIII (CD16) triggers effective lysis of lymphoma cells. Br J Haematol 125:167–179
53. Hombach A, Jung W, Pohl C et al (1993) A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin’s cells by unstimulated natural killer cells in vitro and in vivo. Int J Cancer 55:830–836
54. Renner C, Pfreundschuh M (1995) Treatment of heterotransplanted Hodgkin’s tumors in SCID mice by a combination of human NK or T cells and bispecific antibodies. J Hematother 4:447–451
55. Sahin U, Kraft-Bauer S, Ohnesorge S et al (1996) Interleukin-12 increases bispecificantibody- mediated natural killer cell cytotoxicity against human tumors. Cancer Immunol Immunother 42:9–14
56. Renner C, Hartmann F, Pfreundschuh M (1997) Treatment of refractory Hodgkin’s disease with an anti-CD16/CD30 bispecific antibody. Cancer Immunol Immunother 45:184–186
57. Hartmann F, Renner C, Jung W et al (1997) Treatment of refractory Hodgkin’s disease with an anti-CD16/CD30 bispecific antibody. Blood 89:2042–2047
58. Hartmann F, Renner C, Jung W et al (1998) Anti-CD16/CD30 bispecific antibodies as possible treatment for refractory Hodgkin’s disease. Leuk Lymphoma 31:385–392
59. da Costa L, Renner C, Hartmann F et al (2000) Immune recruitment by bispecific antibodies for the treatment of Hodgkin disease. Cancer Chemother Pharmacol 46(Suppl):S33–S36
60. Renner C, Hartmann F, Jung W et al (2000) Initiation of humoral and cellular immune responses in patients with refractory Hodgkin’s disease by treatment with an anti-CD16/ CD30 bispecific antibody. Cancer Immunol Immunother 49:173–180
61. Reiners KS, Kessler J, Sauer M et al (2013) Rescue of impaired NK cell activity in Hodgkin lymphoma with bispecific antibodies in vitro and in patients. Mol Ther 21:895–903
62. Arndt MA, Krauss J, Kipriyanov SM et al (1999) A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplantated human Hodgkin’s tumors. Blood 94:2562–2568
63. Ferrini S, Cambiaggi A, Sforzini S et al (1993) Use of anti-CD3 and anti-CD16 bispecific monoclonal antibodies for the targeting of T and NK cells against tumor cells. Cancer Detect Prev 17:295–300
64. Elsasser D, Stadick H, Stark S et al (1999) Preclinical studies combining bispecific antibodies with cytokine-stimulated effector cells for immunotherapy of renal cell carcinoma. Anticancer Res 19:1525–1528
65. Weiner LM, Clark JI, Davey M et al (1995) Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. Cancer Res 55:4586–4593
66. Weiner LM, Clark JI, Ring DB et al (1995) Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. J Hematother 4:453–456
67. Shahied LS, Tang Y, Alpaugh RK et al (2004) Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format. J Biol Chem 279:53907–53914
68. Xie Z, Shi M, Feng J et al (2003) A trivalent anti-erbB2/anti-CD16 bispecific antibody retargeting NK cells against human breast cancer cells. Biochem Biophys Res Commun 311:307–312
69. Stockmeyer B, Valerius T, Repp R et al (1997) Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer. Cancer Res 57:696–701
70. Weiner LM, Holmes M, Adams GP et al (1993) A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD 16. Cancer Res 53:94–100
71. Weiner LM, Holmes M, Richeson A et al (1993) Binding and cytotoxicity characteristics of the bispecific murine monoclonal antibody 2B 1. J Immunol 151:2877–2886
72. Ferrini S, Prigione I, Miotti S et al (1991) Bispecific monoclonal antibodies directed to CD16 and to a tumor-associated antigen induce target-cell lysis by resting NK cells and by a subset of NK clones. Int J Cancer 48:227–233
73. Gleason MK, Verneris MR, Todhunter DA et al (2012) Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production. Mol Cancer Ther 11:2674–2684
74. Wiernik A, Foley B, Zhang B et al (2013) Targeting Natural Killer Cells to Acute Myeloid Leukemia In Vitro with a CD16 x 33 Bispecific Killer Cell Engager and ADAM17 Inhibition. Clin Cancer Res 19:3844–3855
75. Gleason MK, Ross JA, Warlick ED et al (2014) CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. Blood 123:3016–3026
76. Vallera DA, Zhang B, Gleason MK et al (2013) Heterodimeric Bispecific Single-Chain Variable-Fragment Antibodies Against EpCAM and CD16 Induce Effective Antibody- Dependent Cellular Cytotoxicity Against Human Carcinoma Cells. Cancer Biother Radiopharm 28(4):274–282
77. Chen X, Zaro JL, Shen WC (2013) Fusion protein linkers: property, design and functionality. Adv Drug Deliv Rev 65:1357–1369
78. Huston JS, Levinson D, Mudgett-Hunter M et al (1988) Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci U S A 85:5879–5883
79. Whitlow M, Bell BA, Feng SL et al (1993) An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability. Protein Eng 6:989–995
80. Jager V, Bussow K, Wagner A et al (2013) High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells. BMC Biotechnol 13:52
81. Sorensen HP, Mortensen KK (2005) Advanced genetic strategies for recombinant protein expression in Escherichia coli. J Biotechnol 115:113–128
82. Nakayama H, Shimamoto N (2014) Modern and simple construction of plasmid: saving time and cost. J Microbiol 52:891–897
83. Gibson DG, Benders GA, Andrews-Pfannkoch C et al (2008) Complete chemical synthesis, assembly, and cloning of a Mycoplasma genitalium genome. Science 319:1215–1220
84. Gopal GJ, Kumar A (2013) Strategies for the production of recombinant protein in Escherichia coli. Protein J 32:419–425
85. Burgess RR (2009) Refolding solubilized inclusion body proteins. Methods Enzymol 463:259–282
86. Lichty JJ, Malecki JL, Agnew HD et al (2005) Comparison of affinity tags for protein purification. Protein Expr Purif 41:98–105
87. Kim JY, Kim YG, Lee GM (2012) CHO cells in biotechnology for production of recombinant proteins: current state and further potential. Appl Microbiol Biotechnol 93:917–930
88. Reff ME, Carner K, Chambers KS et al (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD 20. Blood 83:435–445
89. Harrison D, Phillips JH, Lanier LL (1991) Involvement of a metalloprotease in spontaneous and phorbol ester-induced release of natural killer cell-associated Fc gamma RIII (CD16-II). J Immunol 147:3459–3465
90. Borrego F, Lopez-Beltran A, Pena J et al (1994) Downregulation of Fc gamma receptor IIIA alpha (CD16-II) on natural killer cells induced by anti-CD16 mAb is independent of protein tyrosine kinases and protein kinase C. Cell Immunol 158:208–217
91. Grzywacz B, Kataria N, Verneris MR (2007) CD56(dim)CD16(+) NK cells downregulate CD16 following target cell induced activation of matrix metalloproteinases. Leukemia 21:356–359, author reply 359
92. Liu Q, Sun Y, Rihn S et al (2009) Matrix metalloprotease inhibitors restore impaired NK cell-mediated antibody-dependent cellular cytotoxicity in human immunodeficiency virus type 1 infection. J Virol 83:8705–8712
93. Edsparr K, Speetjens FM, Mulder-Stapel A et al (2010) Effects of IL-2 on MMP expression in freshly isolated human NK cells and the IL-2-independent NK cell line YT. J Immunother 33:475–481
94. Romee R, Foley B, Lenvik T et al (2013) NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease- 17 (ADAM17). Blood 121:3599–3608
95. Zhou Q, Gil-Krzewska A, Peruzzi G et al (2013) Matrix metalloproteinases inhibition promotes the polyfunctionality of human natural killer cells in therapeutic antibody-based anti-tumour immunotherapy. Clin Exp Immunol 173:131–139
96. Romee R, Leong JW, Fehniger TA (2014) Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer. Scientifica (Cairo) 2014:205796